Thyroid CancerH.-J. Biersack, F. Grünwald Springer Science & Business Media, 4 okt. 2005 - 363 sidor One of the main reasons for publishing this second edition of “T- roid Cancer” is the fact that the first edition has sold out. Furth- more, during the 4 years following the publication of the first edition in 2001, some progress, mainly in the basic sciences (molecular biology), has been made. The most prominent change in the clinical sciences has been the new classification of thyroid cancer, especially with relation to T1–T3 tumors. Now, tumors with a diameter of up to 2 cm are still classified T1. This new UICC classification (6th edition) follows the classification of the American Society of Pathology. These changes require a modification of the old guidelines. According to the Hedinger classification (1988) tumors with a diameter below 1 cm were classified as “papillary microcarcinoma of the thyroid”. Only in those tumors was total or nearly total thyroidectomy deemed unn- essary and I-131 therapy not a prerequisite for treatment. The majority of the chapters has been updated including references to many new publications. Two new chapters, on I-124 PET and - simetry, have been added. We strongly feel that this second edition of “Thyroid Cancer” is again a state-of-the-art overview of the diagnosis and treatment of thyroid cancer. Bonn, Frankfurt am Main H. -J. Biersack, F. Grünwald Preface to the First Edition Thyroid cancer was first described at the end of the eighteenth c- tury. |
Innehåll
Basics | 3 |
Histopathology Immunohistochemistry | 29 |
Familial Differentiated Carcinoma of the Thyroid | 57 |
The Diagnosis of Thyroid Cancer | 71 |
The Current Surgical Approach | 82 |
Differentiated Thyroid Cancer | 95 |
124I Positron Emission Tomographic Dosimetry | 127 |
External Beam Radiotherapy | 139 |
Thyroglobulin as Specific Tumor Marker | 221 |
Functional Imaging of Thyroid Cancer 239 | 238 |
Magnetic Resonance Imaging | 251 |
Thyroid Cancer in Chernobyl Children | 283 |
Medullary Thyroid Cancer | 295 |
Imaging in Medullary Thyroid Cancer | 311 |
Scintigraphy Positron Emission Tomography | 321 |
Therapy for Medullary Thyroid Cancer 335 | 334 |
Treatment with Thyroid Hormone | 163 |
Redifferentiation Therapy of Thyroid Carcinomas | 187 |
Followup of Patients with WellDifferentiated | 198 |
Followup of Medullary Thyroid Cancer | 347 |
357 | |
Vanliga ord och fraser
ablation activity analysis anaplastic assay associated body bone calcitonin cell changes chemotherapy Clin Endocrinol Metab clinical combination compared contrast demonstrated detection diagnostic differentiated thyroid cancer differentiated thyroid carcinoma disease dose doxorubicin effect et al evaluation expression external factors familial findings follicular follow-up frequent gene Germany higher histological human hypothyroid imaging incidence increase indicate iodine Italy lesions less levels lymph node malignant measurement medullary thyroid carcinoma metastases mutations neck nodules normal Nucl papillary carcinoma papillary thyroid carcinoma patients performed present primary prognostic radiation radioiodine radiotherapy recent receptor recurrence reported response risk scan scintigraphy sensitivity serum showed shown significant specific sporadic stage stimulation suppression Surg surgery surgical Table therapeutic therapy thyroglobulin thyroid gland thyroid hormone thyroidectomy tion tissue treated treatment tumor uptake values weeks